GENEVA, Sept. 24 -- BN PHARMACEUTICALS INC. filed a patent application (EP2026/057940) for “RADIOLIGAND THERAPIES COMPRISING ALPHA-EMITTING RADIONUCLIDES, MACROCYCLIC CHELATORS, TARGETING LIGANDS, AND ALBUMIN-BINDING MOIETIES FOR TREATMENT OF CANCER”. With publication no. WO/2026/195870, here are the other details related to the patent application:
Kind: Initial Publication with ISR [A1]
IPC: A61K 51/08
Notably, the patent application was submitted under the International Patent Classification (IPC) system, which is managed by the World Intellectual Property Organization (WIPO).
Disclaimer: Curated by HT Syndication....